Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
NCT04918147 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE2 · terminated · last registry update 2026-02-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLAMF7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-19Phase 3 first posted: CellCentric Ltd., InoPd + Investigator's choice of SAT (NCT07772024)
- 2026-04-29Phase 3 first posted: Hoffmann-La Roche, Cevostamab + Pomalidomide (NCT07555938)
- 2026-01-05Also stopped (terminated): Universitätsklinikum Hamburg-Eppendorf, Allogeneic Stem Cells + carfilzomib/lenalidomide/dexamethasone (KRD) (NCT05675319)
- 2025-09-10Results posted on the registry: University of Chicago, Elotuzumab + Carfilzomib (NCT02969837)
- 2025-06-24Results posted on the registry: Mayo Clinic, Dexamethasone + Elotuzumab (NCT03713294)
- 2025-05-09Results posted on the registry: M.D. Anderson Cancer Center, Elotuzumab + Lenalidomide (NCT01729091)
- 2025-02-14Also stopped (terminated): Multiple Myeloma Research Consortium, Elotuzumab, pomalidomide, dexamethasone + Anti-LAG-3 (NCT04150965)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision